RU2115650C1
(ru)
*
|
1992-11-09 |
1998-07-20 |
Дзе Бутс Компани ПЛС |
2,3,4,5-тетрагидро-1,4-бензотиазепины, их стереоизомеры или их фармацевтически приемлемые соли, способ их получения, фармацевтическая композиция, обладающая противосудорожным действием
|
ZA941003B
(en)
*
|
1993-02-15 |
1995-08-14 |
Wellcome Found |
Hypolipidaemic compounds
|
IL108634A0
(en)
*
|
1993-02-15 |
1994-05-30 |
Wellcome Found |
Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
|
AU678503B2
(en)
*
|
1993-09-24 |
1997-05-29 |
Takeda Chemical Industries Ltd. |
Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
|
ZA956647B
(en)
*
|
1994-08-10 |
1997-02-10 |
Wellcome Found |
Hypolipidaemic compounds.
|
DE69520364T2
(de)
*
|
1994-09-13 |
2001-09-13 |
Monsanto Company, St. Louis |
Benzothepines mit wirkung als inhibitoren des gallensäuretransports und der taurocholate-aufnahme
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6107494A
(en)
*
|
1994-09-13 |
2000-08-22 |
G.D. Searle And Company |
Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US5994391A
(en)
*
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
GB9423172D0
(en)
*
|
1994-11-17 |
1995-01-04 |
Wellcom Foundation The Limited |
Hypolipidemic benzothiazepines
|
GB9616279D0
(en)
*
|
1996-08-02 |
1996-09-11 |
Knoll Ag |
Chemical process
|
GB9704208D0
(en)
*
|
1997-02-28 |
1997-04-16 |
Glaxo Group Ltd |
Chemical compounds
|
MXPA99008417A
(es)
*
|
1997-03-11 |
2005-02-03 |
Searle & Co |
Terapia de combinacion que emplaza benzotiepinas inhibidoras de transporte de acido biliar ileal e inhibidores de hmg co-a reductasa.
|
ATE242258T1
(de)
*
|
1997-03-14 |
2003-06-15 |
Aventis Pharma Gmbh |
Hypolipidemische 1,4-benzothiazepin-1,1-dioxide
|
DE59811528D1
(de)
*
|
1997-04-04 |
2004-07-15 |
Aventis Pharma Gmbh |
Hypolipidämische Propanolaminderivate
|
US6221897B1
(en)
|
1998-06-10 |
2001-04-24 |
Aventis Pharma Deutschland Gmbh |
Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
|
DE19845403B4
(de)
*
|
1998-10-02 |
2005-02-10 |
Aventis Pharma Deutschland Gmbh |
Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
DE19845405C2
(de)
|
1998-10-02 |
2000-07-13 |
Aventis Pharma Gmbh |
Arylsubstituierte Propanolaminderivate und deren Verwendung
|
DE19845406C2
(de)
*
|
1998-10-02 |
2001-10-18 |
Aventis Pharma Gmbh |
Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
HK1045114A1
(zh)
|
1998-12-23 |
2002-11-15 |
G‧D‧瑟尔有限公司 |
适用於心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合
|
ATE242007T1
(de)
|
1998-12-23 |
2003-06-15 |
Searle Llc |
Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
|
ATE242009T1
(de)
|
1998-12-23 |
2003-06-15 |
Searle Llc |
Kombinationen von cholesteryl ester transfer protein inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
|
DE69908644T2
(de)
|
1998-12-23 |
2004-05-13 |
G.D. Searle Llc, Chicago |
Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
|
BR9916564A
(pt)
*
|
1998-12-23 |
2002-01-29 |
Searle Llc |
Combinações para indicações cardiovasculares
|
AU2157400A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
|
JP2002533412A
(ja)
|
1998-12-23 |
2002-10-08 |
ジー.ディー.サール エルエルシー |
心臓血管に適用するための回腸胆汁酸輸送阻害剤およびコレステリルエステル転送タンパク質阻害剤の組み合わせ
|
AU776953B2
(en)
*
|
1998-12-23 |
2004-09-30 |
G.D. Searle Llc |
Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
|
DE19916108C1
(de)
*
|
1999-04-09 |
2001-01-11 |
Aventis Pharma Gmbh |
Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
|
GB9914745D0
(en)
*
|
1999-06-24 |
1999-08-25 |
Knoll Ag |
Therapeutic agents
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
WO2001068096A2
(en)
*
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
US6794544B2
(en)
|
2000-03-10 |
2004-09-21 |
Pharmacia Corporation |
Method for the preparation of tetrahydrobenzothiepines
|
AU4941501A
(en)
|
2000-03-24 |
2001-10-08 |
Pharmacia Corp |
Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
|
US6956131B2
(en)
|
2000-04-13 |
2005-10-18 |
Pharmacia Corporation |
2-amino-3, 4 heptenoic compounds useful as nitric oxide synthase inhibitors
|
AR034120A1
(es)
|
2000-04-13 |
2004-02-04 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
|
AR030416A1
(es)
|
2000-04-13 |
2003-08-20 |
Pharmacia Corp |
COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
|
US6545170B2
(en)
|
2000-04-13 |
2003-04-08 |
Pharmacia Corporation |
2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
|
AR032318A1
(es)
|
2000-04-13 |
2003-11-05 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
|
US6787668B2
(en)
|
2000-04-13 |
2004-09-07 |
Pharmacia Corporation |
2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
|
US6489125B1
(en)
*
|
2000-05-10 |
2002-12-03 |
The Trustees Of Columbia University In The City Of New York |
Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
|
US7718644B2
(en)
*
|
2004-01-22 |
2010-05-18 |
The Trustees Of Columbia University In The City Of New York |
Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
|
US7879840B2
(en)
*
|
2005-08-25 |
2011-02-01 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the RyR receptors
|
US7312044B2
(en)
|
2003-03-07 |
2007-12-25 |
The Trustees Of Columbia University In The City Of New York |
Type 1 ryanodine receptor-based methods
|
US20060293266A1
(en)
*
|
2000-05-10 |
2006-12-28 |
The Trustees Of Columbia |
Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
|
US20040048780A1
(en)
*
|
2000-05-10 |
2004-03-11 |
The Trustees Of Columbia University In The City Of New York |
Method for treating and preventing cardiac arrhythmia
|
US8022058B2
(en)
|
2000-05-10 |
2011-09-20 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the RyR receptors
|
US20040229781A1
(en)
*
|
2000-05-10 |
2004-11-18 |
Marks Andrew Robert |
Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
|
US7393652B2
(en)
*
|
2000-05-10 |
2008-07-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
|
US20020183307A1
(en)
*
|
2000-07-26 |
2002-12-05 |
Tremont Samuel J. |
Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
|
AR031129A1
(es)
|
2000-09-15 |
2003-09-10 |
Pharmacia Corp |
Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
|
AR030741A1
(es)
|
2000-09-15 |
2003-09-03 |
Pharmacia Corp |
Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
WO2002083944A2
(en)
*
|
2001-04-17 |
2002-10-24 |
Astrazeneca Ab |
Chemical compounds for identification of slc10a2 gene polymorphisms
|
US20040072903A1
(en)
*
|
2001-05-08 |
2004-04-15 |
Auerbach Bruce Jeffrey |
Carboxyalkylether-acat inhibitors combinations
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
GB0121337D0
(en)
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
TWI331143B
(en)
|
2001-09-08 |
2010-10-01 |
Astrazeneca Uk Ltd |
Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them
|
MXPA04003524A
(es)
*
|
2001-11-02 |
2004-07-23 |
Searle Llc |
Compuestos de benzotiepina monofluorados y difluorados novedosos como inhibidores de transporte de acido biliar co-dependiente de sodio apical (asbt) y captacion de taurocolato.
|
JP2005521653A
(ja)
|
2002-01-17 |
2005-07-21 |
ファルマシア コーポレイション |
先端ナトリウム同時依存性胆汁酸輸送(asbt)およびタウロコール酸塩取込みの阻害剤としての新規アルキル/アリールヒドロキシまたはケトチエピン化合物
|
GB0209467D0
(en)
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
GB0213669D0
(en)
|
2002-06-14 |
2002-07-24 |
Astrazeneca Ab |
Chemical compounds
|
US7312208B2
(en)
|
2002-08-28 |
2007-12-25 |
Asahi Kasei Pharma Corporation |
Quaternary ammonium compounds
|
US7544678B2
(en)
*
|
2002-11-05 |
2009-06-09 |
The Trustees Of Columbia University In The City Of New York |
Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
|
GB0304194D0
(en)
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
US8710045B2
(en)
*
|
2004-01-22 |
2014-04-29 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the ryanodine receptors
|
EP1719768B1
(en)
|
2004-02-27 |
2012-04-25 |
Asahi Kasei Pharma Corporation |
Novel benzothiazepine and benzothiepine compounds
|
US7704990B2
(en)
*
|
2005-08-25 |
2010-04-27 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the RyR receptors
|
US9339480B2
(en)
*
|
2008-11-26 |
2016-05-17 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
JO3131B1
(ar)
*
|
2010-04-27 |
2017-09-20 |
Glaxosmithkline Llc |
مركبات كيميائية
|
EP2995317A1
(en)
|
2010-05-26 |
2016-03-16 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
PL3400944T3
(pl)
|
2010-11-04 |
2020-11-16 |
Albireo Ab |
Inhibitory ibat w leczeniu chorób wątroby
|
JP6097695B2
(ja)
|
2010-11-08 |
2017-03-15 |
アルビレオ アクチエボラグ |
Ibat阻害剤および胆汁酸結合剤を含む薬学的組み合わせ
|
KR102051031B1
(ko)
|
2011-10-28 |
2019-12-02 |
루메나 파마수티컬즈, 인코포레이티드 |
고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
|
CA2853285C
(en)
|
2011-10-28 |
2020-05-05 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
CN105228607A
(zh)
|
2013-03-15 |
2016-01-06 |
鲁美纳医药公司 |
用于治疗原发性硬化性胆管炎和炎性肠病的胆汁酸再循环抑制剂
|
US20140271734A1
(en)
|
2013-03-15 |
2014-09-18 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
|
JO3301B1
(ar)
|
2013-04-26 |
2018-09-16 |
Albireo Ab |
تعديلات بلورية على إيلوبيكسيبات
|
KR20220082931A
(ko)
|
2014-06-25 |
2022-06-17 |
이에이 파마 가부시키가이샤 |
고형 제제 및 그의 착색 방지 또는 착색 감소 방법
|
EP3012252A1
(en)
|
2014-10-24 |
2016-04-27 |
Ferring BV |
Crystal modifications of elobixibat
|
RU2750937C2
(ru)
|
2016-02-09 |
2021-07-06 |
Альбирео Аб |
Пероральный состав холестирамина и его применение
|
US10441605B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US10441604B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
RU2750944C2
(ru)
|
2016-02-09 |
2021-07-06 |
Альбирео Аб |
Пероральный состав холестирамина и его применение
|
US10786529B2
(en)
|
2016-02-09 |
2020-09-29 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
WO2019032026A1
(en)
|
2017-08-09 |
2019-02-14 |
Albireo Ab |
CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
|
EP3664782B1
(en)
|
2017-08-09 |
2025-01-29 |
Albireo AB |
Cholestyramine pellets, oral cholestyramine formulations and medical use thereof
|
US10793534B2
(en)
|
2018-06-05 |
2020-10-06 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
WO2019234077A1
(en)
|
2018-06-05 |
2019-12-12 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
CN112262130B
(zh)
|
2018-06-20 |
2024-07-02 |
阿尔比里奥公司 |
奥德昔巴特的结晶修饰物
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
JP7504110B2
(ja)
|
2019-02-06 |
2024-06-21 |
アルビレオ・アクチボラグ |
ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
SMT202300020T1
(it)
|
2019-02-06 |
2023-03-17 |
Albireo Ab |
Composti di benzotiadiazepine e loro uso come modulatori degli acidi biliari
|
US10941127B2
(en)
|
2019-02-06 |
2021-03-09 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
US10975045B2
(en)
|
2019-02-06 |
2021-04-13 |
Aibireo AB |
Benzothiazepine compounds and their use as bile acid modulators
|
AU2020221834A1
(en)
|
2019-02-12 |
2021-09-02 |
Mirum Pharmaceuticals, Inc. |
Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency
|
WO2021110883A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
TWI877262B
(zh)
|
2019-12-04 |
2025-03-21 |
瑞典商艾爾比瑞歐公司 |
苯并噻氮呯化合物及其作為膽酸調節劑之用途
|
ES2972045T3
(es)
|
2019-12-04 |
2024-06-10 |
Albireo Ab |
Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
|
WO2021110884A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
WO2021110886A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
EP4069360B1
(en)
|
2019-12-04 |
2024-01-03 |
Albireo AB |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
CN114761018A
(zh)
|
2019-12-04 |
2022-07-15 |
阿尔比里奥公司 |
苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
AR120682A1
(es)
|
2019-12-04 |
2022-03-09 |
Albireo Ab |
Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
CN114761080B
(zh)
|
2019-12-04 |
2024-07-23 |
阿尔比里奥公司 |
苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
WO2022029101A1
(en)
|
2020-08-03 |
2022-02-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
CA3186857A1
(en)
|
2020-08-03 |
2022-02-10 |
Per-Goran Gillberg |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
JP2023549226A
(ja)
|
2020-11-12 |
2023-11-22 |
アルビレオ エービー |
進行性家族性肝内胆汁うっ滞症(pfic)を処置するためのオデビキシバット
|
EP4255565A1
(en)
|
2020-12-04 |
2023-10-11 |
Albireo AB |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
TW202313579A
(zh)
|
2021-06-03 |
2023-04-01 |
瑞典商艾爾比瑞歐公司 |
苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
|
JP2025516153A
(ja)
|
2022-04-22 |
2025-05-27 |
アルビレオ・アクチボラグ |
Asbt阻害剤の皮下投与
|
AU2023285002A1
(en)
|
2022-06-09 |
2024-12-05 |
Albireo Ab |
Treating hepatitis
|
WO2024008766A1
(en)
|
2022-07-05 |
2024-01-11 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
WO2024121434A1
(en)
|
2022-12-09 |
2024-06-13 |
Albireo Ab |
Asbt inhibitors in the treatment of renal diseases
|
WO2025146507A1
(en)
|
2024-01-05 |
2025-07-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
WO2025146508A1
(en)
|
2024-01-05 |
2025-07-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|